![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Convidecia Air™ (homologous inactivated covid-19 vaccine) has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observed.
Lead Product(s): Homologous Inactivated Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia Air
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: CanSino Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in Greater China.
Lead Product(s): AP-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AeroFact
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Nuance Pharma
Deal Size: $212.5 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement December 22, 2021
Details:
Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine, Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.
Lead Product(s): Convidecia
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: CanSino Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 09, 2021